DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and chlorthalidone (Drug); Azilsartan medoxomil and chlorthalidone (Drug); Chlorthalidone (Drug); Chlorthalidone (Drug); Azilsartan medoxomil (Drug); Azilsartan medoxomil (Drug); Azilsartan medoxomil (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Takeda

Official(s) and/or principal investigator(s):
Executive Medical Director, Study Director, Affiliation: Takeda

Summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.

Clinical Details

Official title: A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)

Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)

Secondary outcome:

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)

Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)

Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.

Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.

Detailed description: According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully. Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker that is being evaluated by Takeda to treat essential hypertension. Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment. This study is designed to compare the antihypertensive effect and the safety and tolerability of the azilsartan medoxomil plus chlorthalidone fixed-dose combination product (TAK 491CLD FDC) with azilsartan monotherapy and chlorthalidone monotherapy during 8 weeks of treatment. Participants in this study will be randomized to receive one of 11 possible dosing combinations of azilsartan medoxomil , chlorthalidone and placebo over an 8 week period. The total duration of the study will be approximately 13 weeks. Participants will make 12 visits to the clinic. Each participant will also be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg on the day prior to randomization, or the participant has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg at the Screening Visit and on the day prior to randomization. 2. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. 3. Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant.

4. Is willing to discontinue current antihypertensive medications on Day - 21 or on Day

- 28 if on amlodipine or chlorthalidone.

Exclusion Criteria: 1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg on the day prior to randomization. 2. Has a baseline 24-hour ambulatory blood pressure measurement reading of insufficient quality. 3. Has works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]). 4. Has an upper arm circumference less than 24 cm or greater than 42 cm. 5. Has is noncompliant with study medication during the placebo run-in period. 6. Has secondary hypertension of any etiology. 7. Has recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack. 8. Has clinically significant cardiac conduction defects. 9. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease. 10. Has severe renal dysfunction or disease. 11. Has known or suspected unilateral or bilateral renal artery stenosis. 12. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. 13. Has poorly controlled type 1 or type 2 diabetes mellitus at Screening. 14. Has hypokalemia or hyperkalemia. 15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than 2. 5 times the upper limit of normal, active liver disease, or jaundice. 16. Has any other known serious disease or condition that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow Has according to the protocol. 17. Has known hypersensitivity to angiotensin II receptor blockers, thiazide-type diuretics or other sulfonamide-derived compounds. 18. Has been randomized in a previous azilsartan medoxomil study. 19. Is currently participating in another investigational study or is receiving or has received any investigational compound within 30 days prior to Screening. 20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.

Locations and Contacts

Santiago, Chile

Temuco, Chile

Aguascalientes, Mexico

Merida, Mexico

Mexico DF, Mexico

Bellavista, Peru

Chiclayo, Peru

Jesus Maria, Peru

Miraflores, Peru

San Borja, Peru

San Martin de Porres, Peru

Trujillo, Peru

Umacollo, Peru

Moscow, Russian Federation

St. Petersburg, Russian Federation

Birmingham, Alabama, United States

Columbiana, Alabama, United States

Tuscaloosa, Alabama, United States

Chandler, Arizona, United States

Phoenix, Arizona, United States

Scottsdale, Arizona, United States

Tucson, Arizona, United States

Little Rock, Arkansas, United States

Buena Park, California, United States

Carmichael, California, United States

Costa Mesa, California, United States

Irvine, California, United States

Palm Springs, California, United States

Riverside, California, United States

Sacramento, California, United States

San Diego, California, United States

Vista, California, United States

Walnut Creek, California, United States

Middletown, Delaware, United States

Bradenton, Florida, United States

Deerfield Beach, Florida, United States

Fort Lauderdale, Florida, United States

Hallandale Beach, Florida, United States

Hialeah, Florida, United States

Jacksonville, Florida, United States

Longwood, Florida, United States

Miami, Florida, United States

Ocala, Florida, United States

Ormond Beach, Florida, United States

St Petersburg, Florida, United States

Atlanta, Georgia, United States

Buffalo Grove, Illinois, United States

Libertyville, Illinois, United States

Melrose Park, Illinois, United States

Fishers, Indiana, United States

Indianapolis, Indiana, United States

Erlanger, Kentucky, United States

Madisonville, Kentucky, United States

Paducah, Kentucky, United States

Rockville, Maryland, United States

Ann Arbor, Michigan, United States

Chesterfield, Michigan, United States

St Louis, Missouri, United States

Omaha, Nebraska, United States

Henderson, Nevada, United States

Brick, New Jersey, United States

Margate, New Jersey, United States

Albuquerque, New Mexico, United States

Endwell, New York, United States

Cary, North Carolina, United States

Winston-Salem, North Carolina, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Dayton, Ohio, United States

Lyndhurst, Ohio, United States

Willoughby Hills, Ohio, United States

Oklahoma City, Oklahoma, United States

Ashland, Oregon, United States

Altoona, Pennsylvania, United States

Bensalem, Pennsylvania, United States

Feasterville, Pennsylvania, United States

Jenkintown, Pennsylvania, United States

Sellersville, Pennsylvania, United States

Warminster, Pennsylvania, United States

Charleston, South Carolina, United States

Florence, South Carolina, United States

Murrells Inlet, South Carolina, United States

Simpsonville, South Carolina, United States

Spartanburg, South Carolina, United States

Clarksville, Tennessee, United States

New Tazewell, Tennessee, United States

Austin, Texas, United States

Bellaire, Texas, United States

Dallas, Texas, United States

Houston, Texas, United States

McKinney, Texas, United States

Richardson, Texas, United States

San Antonio, Texas, United States

Magna, Utah, United States

West Jordan, Utah, United States

Arlington, Virginia, United States

Virginia Beach, Virginia, United States

Oregon, Wisconsin, United States

Additional Information

EDARBYCLOR Package Insert

FDA Safety Alerts and Recalls

Starting date: January 2009
Last updated: January 4, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017